ATE394122T1 - Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen - Google Patents

Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen

Info

Publication number
ATE394122T1
ATE394122T1 AT04709605T AT04709605T ATE394122T1 AT E394122 T1 ATE394122 T1 AT E394122T1 AT 04709605 T AT04709605 T AT 04709605T AT 04709605 T AT04709605 T AT 04709605T AT E394122 T1 ATE394122 T1 AT E394122T1
Authority
AT
Austria
Prior art keywords
treatment
injuries
ligand
inhibition
receptor system
Prior art date
Application number
AT04709605T
Other languages
English (en)
Inventor
Ana Martin-Villalba
Peter Krammer
Deana Demjen
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE394122T1 publication Critical patent/ATE394122T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Steroid Compounds (AREA)
AT04709605T 2003-02-14 2004-02-10 Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen ATE394122T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03003426A EP1447093A1 (de) 2003-02-14 2003-02-14 Inhibition des CD95 Ligand/Rezeptorsystems zur Behandlung neurologischer Störungen und Verletzungen

Publications (1)

Publication Number Publication Date
ATE394122T1 true ATE394122T1 (de) 2008-05-15

Family

ID=32668981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709605T ATE394122T1 (de) 2003-02-14 2004-02-10 Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen

Country Status (10)

Country Link
US (1) US7935339B2 (de)
EP (2) EP1447093A1 (de)
JP (1) JP4800920B2 (de)
AT (1) ATE394122T1 (de)
AU (1) AU2004212308C1 (de)
CA (1) CA2514794C (de)
DE (1) DE602004013540D1 (de)
DK (1) DK1592446T3 (de)
ES (1) ES2301966T3 (de)
WO (1) WO2004071528A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064501A1 (es) 2006-12-22 2009-04-08 Genentech Inc Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
SI2428252T1 (sl) 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
WO2010006772A2 (en) * 2008-07-14 2010-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
US20110110942A1 (en) 2009-11-12 2011-05-12 Genentech, Inc. Method of promoting dendritic spine density
AU2016341529B2 (en) 2015-10-22 2023-03-30 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN111546719B (zh) * 2020-04-21 2022-07-01 中国船舶重工集团公司第七二五研究所 一种磁性宽频带电磁吸波超材料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4447484C2 (de) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
CN1196733A (zh) 1995-06-30 1998-10-21 持田制药株式会社 抗Fas配体抗体和利用抗Fas配体抗体的测定方法
CA2270423C (en) 1996-10-31 2009-09-15 Mochida Pharmaceutical Co., Ltd. Prophylactic/therapeutic agent
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
JP4303883B2 (ja) * 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
AU3739500A (en) * 1999-03-30 2000-10-16 Eli Lilly And Company Protease resistant flint analogs
WO2000072707A1 (en) * 1999-05-26 2000-12-07 Ikuo Toratani Clothing such as shorts and bathing suit
DE19959049A1 (de) * 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
AU2001249619B2 (en) * 2000-03-29 2006-08-17 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
US7115717B2 (en) * 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies

Also Published As

Publication number Publication date
CA2514794C (en) 2013-05-28
WO2004071528A1 (en) 2004-08-26
JP4800920B2 (ja) 2011-10-26
JP2006517559A (ja) 2006-07-27
AU2004212308C1 (en) 2009-10-29
DK1592446T3 (da) 2008-09-01
EP1592446B1 (de) 2008-05-07
US7935339B2 (en) 2011-05-03
ES2301966T3 (es) 2008-07-01
DE602004013540D1 (de) 2008-06-19
AU2004212308B2 (en) 2009-05-21
AU2004212308A1 (en) 2004-08-26
CA2514794A1 (en) 2004-08-26
EP1447093A1 (de) 2004-08-18
US20060234968A1 (en) 2006-10-19
EP1592446A1 (de) 2005-11-09

Similar Documents

Publication Publication Date Title
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE602004008069D1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ATE394122T1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
DE60219687D1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
TW200735868A (en) Compositions and methods for treating CNS disorders
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1592446

Country of ref document: EP

REN Ceased due to non-payment of the annual fee